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Abstract 
Moderate ethanol preconditioning, a result of prolonged moderate alcohol 
intake, serves as a protective process by staving off cognitive decline while 
providing neuronal protection through several mechanisms. These individual 
mechanisms are relatively well known, however a comprehensive and 
integrated conversation of ethanol’s protective tendencies is lacking from 
literature and the field of neuroscience. First, a review of the leading theories 
behind moderate ethanol preconditioning’s biological and cognitive benefits is 
presented, including overviews of neuroprotective, antioxidant, and 
neurotropic mechanisms responsible for neurological benefit. Secondly, an 
integrative model is presented, incorporating all research into a novel 
collaborative model. An additional discussion regarding the efficacy of 
ethanol treatments follow the comprehensive and integrated model. 
Introduction 
Current Alzheimer’s disease (AD) projections estimate prevalence rates to 
quadruple by 2047, inevitably resulting in the diagnosis of nearly 1 in 45 
Americans over the next three decades (Herbert et al., 2003). AD is the sixth 
leading cause of death in the United States, and will soon establish itself as 
an even greater social and economic burden. In attempt to mitigate this 
impending affliction, extensive research has been conducted in identifying 
potential risk factors and protectants for the AD pathology and associated 
cognitive decline. Some prominent risk factors have been identified as obesity 
(Whitmer et al., 2008), elevated cholesterol levels (Soloman et al., 2009), 
vascular conditions such as diabetes and hypertension (Richard et al., 2012), 
family history of the pathology (Lautenschlager et al., 1996), and traumatic 
brain injury (Giunta et al., 2012). Additionally, cardiovascular exercise 
(Agevaren et al., 2008) and healthy diet containing proper nutrients (Gu et 
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al., 2010) can serve as effect promoters of cognitive functioning and protect 
individuals from cognitive decline and dementia. One possible protective 
factor, in particular interest to this paper, has raised much debate within the 
aging and mental health research community: Alcohol consumption. 
 Numerous studies have shown a protective effect of alcohol intake on 
cognitive decline and AD related dementia (Peters et al., 2008; Piazza-Garner 
et al., 2013; Anstey et al., 2009). In this critical review, we will examine 
alcohol’s effects on AD and cognitive function starting from the cellular level 
before expanding our search for broader implications. Additionally, this paper 
will be focusing exclusively on ethanol’s effects in aging and cognitive decline. 
All consumable alcohol contains ethanol, which must be investigated 
independently in order to control for the wide variety of beverages consumed 
(e.g. wine or beer). For example, wine inherently contains components such 
as polyphenols that could enhance its protective effects (Wang et al., 2006). 
Polyphenols and other proposed beneficial components of alcoholic beverages 
will not be discussed further, and the interaction between ethanol and the 
AD pathology will be exclusively investigated. Furthermore, some proponents 
suggest that ethanol is the sole contributor to alcohol’s protective effects, 
even in wines (Klatsky et al., 1997). This established, this paper has three 
main goals: (1) investigate ethanol’s protective effects at the cellular level and 
suggest a new integrated biological model scheme, (2) identify additional 
methods in which ethanol could serve as a protectant, and (3) determine if 
ethanol could be used as an appropriate intervention for cognitive decline 
associated with AD related dementia.  
Moderate Ethanol Preconditioning 
The biological response to ethanol consumption must be examined in order to 
understand the cognitive benefits of alcohol ingestion. Therefore, we must 
first investigate ethanol’s neurobiological impact. It is known that subjecting 
a biological construct to repeated subtoxic injury over time can result in a 
phenomenon known as Preconditioning (Kalev-Zylinska et al., 2007). 
Preconditioning is the leading theory of how ethanol helps preserve our 
cognitive functioning and serves as an active neuroprotective agent. Ethanol 
conditions a particular glutamate receptor, the N-methyl-D-aspartate 
receptor (NMDAR), by acting as an antagonist. When individuals consume 
alcohol at a moderate/low-level over a long period of time, NMDAR is 
conditioned to this constant suppression, ultimately resulting in upregulation 
and increased activation of the receptor (Kalev-Zylinska et al., 2007). This 
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paradoxical process is called Moderate Ethanol Preconditioning (MEP). Once 
the NMDAR establishes a chronic increase in activation, a direct result of 
MEP, several downstream processes begin that result in the production of 
multiple protective factors that combat AD pathology, dementia, and 
cognitive decline. This established, we will now review the specific 
mechanisms downstream from MEP and determine the particular biological 
consequences of chronic low-level ethanol intake. 
MEP: NEUROPROTECTIVE MECHANISM 
Moderate ethanol consumption may combat emerging cognitive decline 
during aging and AD by targeting neuroinflammation related to 
amyloidogenic protein accumulation. This accumulation of β-amyloid (Aβ) is 
responsible for the plaques seen in AD, neurodegeneration caused by 
increases in Ca2+, and proinflammatory mediators (Collins et al., 2010). In 
order to effectively combat Aβ toxicity through MEP, NMDAR activity must 
create a downstream byproduct that directly affects neurodegeneration 
caused by this protein aggregation. In Vitro studies targeting hippocampal-
entorhinal cortical (HEC) slices have discovered one method of 
neuroprotection via increases in NMDAR activity, resulting in the production 
of heat shock protein 70 (HSP70) (Collins et al., 2010). HSP70 levels highly 
correlate with protection against various cell-damaging outcomes, including 
ischemia, glutamate excitotoxicity, and reactive oxygen species (Belmandani 
et al., 2004). Furthermore, it is suggested that HSP70 directly inhibits 
apoptosis by diminishing Aβ’s neurotoxicity (Belmandani et al., 2004). 
Although they are correlated, the downstream process from NMDAR activity 
to upregulation of HSP70 is not direct, and requires the involvement of 
mediators. These mediating factors must be established in order to 
sufficiently understand ethanol’s part in HSP70 production.  
 After successfully preconditioning HEC slices (subjecting cultures to 
20-30 mM ethanol for 6 days), immunoblot analyses showed significant 
upregulation of all NDMAR subunits (NR1, NR2B, NR2C) (Collins et al., 
2010). After inducing MEP, several possible mediators where measured at 
days 2, 4, and 6. One protein in particular, Protein Kinase C epsilon type 
(PKCɛ), highly correlated with the up regulation of the NMDAR and showed 
increases of 15% (at day 2), 40% (at day 4), and 200% (at day 6) (Collins et al., 
2010). This large increase suggests that PKCɛ is directly downstream from 
NMDAR and is further established by a NR1 knockdown using memantine, 
which simultaneously antagonized both the NMDAR and PKCɛ expressions. 
Additionally, the use of a pan-PKC inhibitor significantly suppressed both 
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PKCɛ and HSP70, further restoring toxicity and establishing PKCɛ as an 
upstream mediator of HSP70 (Collins et al., 2010). However, the link between 
PKCɛ and HSP70 still requires upregulation of one more mediator, focal 
adhesion kinase (FAK). Western blot analyses of FAK in HEC cultures 
showed a significantly increase that correlated flawlessly with PKCɛ 
upregulation (Collins et al., 2010). Additionally, using PKC isoforms, Collins 
et al., (2010) were able to show that PKCɛ was at least indirectly responsible 
for the increases in FAK (Collins et al., 2010). Furthermore, the use of the 
dominant negative FAK (FRNK) was used to establish the link between FAK 
and HSP70. FRNK expression greatly reduced MEP-mediated increases in 
HSP70 (Collins et al., 2010). These findings result in the neuroprotective 
upregulation of HSP70 that began with the increased activation of NMDAR, 
which in turn initialized the increased production of PKCɛ and FAK, 
respectively. 
MEP: ANTIOXIDANT MECHANISM 
In addition to Aβ burden, oxidative stress accumulates in aging and is 
involved in the pathogenesis of AD. Antioxidants that protect cells from 
stressors (e.g peroxides) may serve as important protective factors of 
cognition and neuronal longevity. Papadia et al., (2008) investigated the 
antioxidants that are boosted in result of NMDAR activity. Mice injected with 
dizocilpine (MK-801), an uncompetitive antagonist of NMDAR, experienced 
widespread neuronal death due to oxidative damage (Papadia et al., 2008). 
Additionally, upregulation of NMDAR resulted in increased protection from 
oxidative stressors such as peroxides (Papadia et al., 2008). This establishes 
that NMDAR, and in turn MEP, initiate a downstream process resulting in 
antioxidative properties.  
 NMDAR activity protects neuronal damage from oxidative stress by 
directly targeting the thioredoxin-Prx system. Periaxins (Prxs) serve as 
cytoprotective and antioxidative proteins, in particular PrxII, PrxIII, and 
PrxIV (Rhee et al., 2007). Prxs contain a peroxidatic cysteine residue, which 
in turn oxidize harmful peroxides to form cystein sulfenic acid (-SOH). This 
cysteine sulfenic acid then forms a disulfide bond with the resolving cysteine, 
which is in turn reduced by thioredoxin (Wood et al., 2003). However, during 
pathogenesis, oxidative stress can increase and over-oxidization of the Prxs 
result in sulfinic (-SO²H) or sulfonic (-SO³H) acid formation (Papadia et al., 
2008). This creates an over-burdened system rendering the peroxidase 
ineffective, allowing for oxidative damage. Typically, thioredoxin facilitates 
the effectiveness of the Prxs, but when sufinic or sufonic acid is formed by 
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increased levels of peroxides, thioredoxin’s effectiveness is rendered useless 
(Papadia et al., 2008). In order to protect from neuronal oxidative stress 
associated with AD and cognitive decline, the reduction of over-oxidized Prxs 
as well as the increase of thioredoxin activity must be established. 
 First, we investigate how NMDAR activity reduces the over-
oxidization of PrxII, PrxIII and PrxIV. Over-oxidization resulting in 
peroxiredoxin sulfinic/sulfonic acid (Prx-SO⅔H) has traditionally thought to 
have been irreversible, however recent studies have suggested that it can be 
reduced back to the catalytically active thiol form by two ATP-dependent 
reductases, sestrin 2 (Sesn2) and sulfiredoxin (Srxn1). Papadia et al., (2008) 
tested this hypothesis, and found positive results. After establishing 
bicuculline, a GABAa receptor antagonist, and 4-aminopyriding, a K+ 
channel antagonist (BiC/4-AP) as an inducer of NMDAR activity, 
downstream effects could be observed. Cortical rat neurons were subjected to 
a brief, high (200μM) dose of hydrogen peroxide in order to induce Prx over-
oxidation (Papadia et al., 2008). BiC/4-AP treated neurons showed a 
significant increase in both Sesn2 and Srxn1. Additionally, induced Sesn2 
and Srxn1 protein and mRNA expressions reduced cell death following 
hydrogen peroxide insult and significantly lowered Prx-SO⅔H (Papadia et al., 
2008). It should be noted that additional knock down tests showed that 
independent increases of Sesn2 and Srxn1 did not find any significant 
results, however the two together showed reliably significant effects. 
 Sesn2 was found to have a multiple binding sites for the transcription 
factor CCAAT enhancer binding protein (C/EBP) (Papadia et al., 2008). After 
several tests using mutations of C/EBP, it was established that Sesn2 is 
largely mediated by C/EBP. Alternatively, Srxn1 is induced by AP-1. BiC/4-
AP stimulation activates the AP-1 sites, and additional knock down studies 
confirmed that Srxn1 is activated via AP-1 sites (Papadia et al., 2008). 
Therefore, Sesn2 is a C/EBP target gene, and Srxn1 is an AP-1 target gene. 
Furthermore, both are upregulated by NMDAR activity and MEP. 
 Furthermore, another important byproduct of increased NMDAR 
activation is the significant decrease in thioredoxin-interacting proteins 
(Txnip). Txnip binds with thioredoxin and inhibits its activity, thus 
promoting vulnerability to oxidative stress (Schulze et al., 2004). Cortical rat 
cultures treated with BiC/4-AP showed a downregulation of Txnip by 60% 
(P=0.01) and displayed successful suppression of this pro-oxidative gene 
expression (Papadia et al., 2008). Investigation of the activity-dependent 
regulation of Txnip revealed that Forkhead Box O (FOXO) is the responsible 
promoter. FOXO phosphorylation turns off Txnip transcription when it is 
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activated by protein kinase B (PkB), which is activated by synaptic NMDAR 
activity (Papadia et al., 2008). Therefore, it is not surprising that BiC/4-AP 
treated cultures showed less FOXO1 and FOXO3a expression, resulting in 
lower Txnip. In conclusion, Txnip is a FOXO target gene that is suppressed 
by NMDAR activity, resulting in an influx of thioredoxin activity and 
protection from oxidative insult. 
MEP: NEUROTROPHIC MECHANISM 
MEP may result in enhanced memory functions. This phenomenon has been 
shown In Vivo in rats fed liquid diets containing no, moderate, or high 
amounts of ethanol (Kalev-Zylinska et al., 2007).This unique animal model 
study exemplifies the paradoxical facilitatory effect of low-dose alcohol intake 
on memory via NMDAR. The abstinent rats (0% ethanol diet), the moderate-
intake rats (2.5% ethanol diet, <17.4 mM BAC) and the high-intake rates (5% 
ethanol diet, 21.8-55.8 mM BAC) proportionally modeled human drinking 
behaviors (Kalev-Zylinska et al., 2007). Subjects were exposed to the novel 
object recognition task (NOR) to examine visual recognition memory and the 
inhibitory avoidance test (IA) to examine associative emotional memory. 
Results showed that memory was enhanced for the 2.5% moderate-intake 
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Figure 1. Proposed Integrated Model of Moderate Ethanol Preconditioning 
Resulting in Cognitive Protection
rats compared to the high-intake and abstinent groups (Kalev-Zylinska et al., 
2007). This observation is reinforced by the knock down of the NR1 subunit of 
NMDAR. All positive effects were negated by NR1 knockdown except for 
emotional memory, and over-intoxication negated all effects in every 
condition (Kalev-Zylinska et al., 2007). The exact mechanism behind this 
phenomenon is unknown, however Kalev-Zylinska et al., (2007) suggest 
facilitation could be due to increases in brain-derived neurotrophic factor 
(BDNF) expression in the moderate-intake rats (Kalev-Zylinska et al., 2007). 
Immunohistochemistry proved difficult, but increases of both BDNF and 
neurotrophic tyrosine kinase (TrkB) protein expressions showed slight but 
significant increases, especially in the NR1 subunit (Kalev-Zylinska et al., 
2007). Both BDNF and TrkB have neurotrophic implications that may result 
in memory facilitation, an observable downstream byproduct of MEP. 
 Combining the neuroprotective, antioxidative, and neurotrophic 
mechanisms downstream from MEP has never been suggested, and the 
resulting model is the first of its kind to integrate various methods resulting 
in cognitive protection. The proposed multi-pronged model of MEP results in 
the suppression of Aβ toxicity, enhanced protection from oxidative damage, 
and improved memory (visual recognition and emotional). In conjuncture, 
these mechanisms could provide protection from cognitive decline associated 
with the AD pathology and actively delay the onset of the disease. 
 The first prong exhibits the decrease in Aβ toxicity, suppressed via 
HSP70 by directly inhibiting neuronal apoptosis. Therefore, HSP70 levels can 
effectively delay negative effects of Aβ plaques, which are implicated in AD. 
Additionally, many studies of aging and cognition regarding AD attribute Aβ 
burden as the primary cause of the pathology and related cognitive decline 
(Peters et al., 2008; Anstey et al., 2009). Staving off accumulation and 
progression of AD and associated decline could enhance cognitive functioning 
and increase functional longevity. In the integrated model, HSP70 is 
increased by the mediators PKCɛ and FAK, and upregulation in each 
respectively are a direct result of increased NMDAR activity. 
 The second mechanism addressed in the model is the reduction of 
oxidative damage through MEP mediated effects on the thioredoxin-Prx 
system. NMDAR activity facilitates antioxidant mechanisms in the 
thioredoxin-Prx system by boosting the effectiveness of thioredoxin while 
increasing unoxidized Prxs. Thioredoxin’s effectiveness is directly inhibited 
by Txnip, resulting in cells being sensitized to H202 induced death (Schulze 
et al., 2004). Additionally, Txnip was found to be a FOXO target gene. This is 
exacerbated in the AD pathological process, where FOXO1 & FOXO3a mRNA 
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levels are further elevated, activating increased levels of Txnip (Blalack et al., 
2004). Therefore our model displays the NMDAR related reduction of FOXO1 
& 3a activity resulting in a downstream process increasing Thioredoxin’s 
efficiency and aiding in the battle against harmful oxidation. Furthermore, 
our model shows MEP mediated decreases in the level of over-oxidized Prxs. 
Two reactivating genes have the unique capability of reversing over-oxidized 
Prxs, resulting in an influx of available antioxidants: Srxn1 and Sesn2. The 
upregulation of both proteins directly influence the level of available PrxII, 
PrxIII, and PrxIV. However, the integrated model is only concerned with 
PrxII and III. Only these two Prxs show cytoprotective effects in cortical 
neurons: PrxII protects neurons against Aβ toxicity and oxygen-glucose 
deprivation, and PrxIII protects hippocampal neurons against excitotoxicity 
(Papadia et al., 2008). These thiol-based antioxidants are increased by Srxn1 
and Sesn2, which are targeted by AP-1 and C/EBP respectively. In turn, we 
display AP-1 and C/EBP upregulation initiated by increased activity in 
NMDAR, resulting in the downstream production of PrxII & III. Together, 
Prx II & III and thioredoxin could provide protection to neurons from 
oxidative damage and preserve cognition by protecting the vital function and 
integrity of cortical neurons.  
 The final branch of our cognitive protection model was observed utilizing 
in vivo studies, whereas the neuroprotective and antioxidant mechanisms 
were investigated primarily using in vitro studies. As discussed above, rats 
that were fed liquid diets with various ethanol-intake levels were subjected to 
emotional and visual memory tasks. It was observed that moderate-intake 
rats performed better than both high-intake and abstinent rats on visual and 
emotional memory tasks. The mediator, proposed in Kalev-Zylinska et al., 
(2007), is the increase of the neurotrophin BDNF causing the activation of 
Trk-B. BDNF has been shown to be vital for long-term memory, the survival 
of existing neurons, and the growth of new neurons and synapses (Acheson et 
al., 2004). Additionally, AD is associated with lowered levels of BDNF and 
several studies suggest that neurotrophic factors such as BDNF protect 
against Aβ toxicity and hippocampal damage (Mattson et al., 2008). In 
particular interest to this paper, Trk-B was found to be most elevated by 
MEP (Kalev-Zylinska et al., 2007). BDNF activates Trk-B, increasing protein 
growth factors that may facilitate memory. This memory facilitation, along 
with other important neurotrophic implications brought on by increases of 
BDNF, constructs our final proposed branch of MEP mediated cognitive 
benefits.  
!63
 In conclusion, there is no single downstream factor established by the 
MEP phenomenon that completely protects cognition, especially when 
pathology like AD is present. Therefore, the integrated model combines 
neuroprotective, antioxidative, and neurotrophic mechanisms in order to 
suggest a more multifaceted approach. By no means does this model propose 
a complete picture, but it does move us one step closer to further 
understanding MEP’s vast array of biologic implications resulting in 
cognitive protection. 
Discussion 
OTHER POSSIBLE PROTECTIVE FACTORS MEDIATED BY MODERATE 
ETHANOL INTAKE 
Moderate ethanol intake initiates many biological processes separate from 
NMDAR activation that may serve as cognitive protectants. The leading 
alternate argument to direct neuronal MEP facilitation is the proven effect of 
moderate ethanol consumption on the vascular system. Many AD risk factors 
in particular, as discussed earlier, are highly associated with vascular 
diseases and conditions. Ischemia, hypertension and obesity are all highly 
correlated with AD related dementia (Peters et al., 2008). This established, 
moderate ethanol intake improves certain vascular processes, thus protecting 
individuals from cognitive decline by lowering AD and dementia incidence. 
 Alcohol’s positive effect on the cardiovascular system is debated; 
however several studies suggest moderate amounts to be protective. Kondo 
(2004), as well as Ecker and Klatsky (2002), exemplify the widely accepted 
fact that moderate alcohol consumption increases high-density cholesterol, 
benefiting the cardiovascular system (Kondo et al., 2004; Ecker et al., 2002). 
Alcohol has also been shown to increase cerebral blood flow and decrease 
blood coagulation (Volkow et al., 2006). Additionally, ethanol has been shown 
to be associated with an anti-inflammatory effect, which would could help 
protect against cardiovascular disease, associated AD, and dementia (Wright 
et al., 2006). In Vivo studies of canine ethanol intake also show reliably 
significant moderate-ethanol induced protection of the myocardium, relieving 
heart tissue from ischemic injury (Pagel et al., 2002). These studies show that 
moderate alcohol intake may be associated with decreasing AD and dementia 
risk by promoting cerebrovascular benefits. However, in many of these 
studies, ethanol was not considered the sole variable in mediating risk factors 
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and future research should be conducted to determine ethanol’s exclusive and 
direct role in cerebrovascular protection. 
 Moderate ethanol consumption is not limited to possible biological 
protective factors and may also serve as a cognitive protectant through more 
social means. Drinking socially could enhance cognitive functions by 
promoting healthy social facilitation. Additionally, studies have found that 
being more social may be protective. Bennett et al., (2006) found that social 
network size and risk of cognitive impairment were inversely correlated, 
suggesting the beneficial effect of friends and family (Bennett et al., 2006). Of 
course this possible protective factor is completely dependent on whether 
individuals find ethanol socially facilitating. Further research must be 
conducted to establish ethanol’s effect on group situations and social 
networks. 
 Another theory of alcohol consumption’s mediating effects include the 
possible facilitation of sleep. Alcohol is widely considered a sleep aid, and 
could possibly promote healthy sleep habits and help maintain a functional 
circadian rhythm, possibly lowering Aβ accumulation in the brain (Ashley et 
al., 2000). Excessive periods of wakefulness increase levels of orexin, which is 
necessary for Aβ production. Additionally, chronic sleep deprivation is 
associated with early onset AD (Kang et al., 2009). However, alcohol-induced 
effects on sleep vary greatly from individual to individual, and can induce 
arousal rather than sedation. Future studies must further investigate 
alcohol’s effects on sleep cycles, circadian rhythm maintenance and Aβ 
accumulation.  
PRESCRIBING ETHANOL: POSSIBLE INTERVENTION 
Through our integrated model of MEP and our discussion of additional 
cognitive benefits derived from moderate ethanol consumption, it can argued 
that low level intake of ethanol over a long period of time can result in 
significant cognitive protection. This establishes ethanol as a viable 
medicinal protectant to stave off AD, dementia, and related cognitive decline. 
Utilized at appropriate levels in conjuncture with exercise and diet, ethanol 
may one day be a staple in the fight against cognitive aging and decline.  
 In addition to pre-symptomatic intake, ethanol may have a role in 
fighting the AD pathology once it is present. As the pathology sets in, the 
brain experiences an influx of glutamate metabolic damage. This excess 
glutamate over excites NMDAR, which causes excitotoxicity by allowing high 
levels of Ca2+ to enter neurons. This may seem counterintuitive to the 
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protective effect of NMDAR activity proposed earlier, but too much Ca2+ 
results in the activation of damaging enzymes rather than initiating 
protective factors. However, ethanol is an NMDAR antagonist, and 
potentially could be used to suppress over-activation. Another NMDAR 
antagonist, memantine, is widely used and accepted as a treatment for 
advanced AD (Papadia et al., 2008). Memantine suppresses Ca2+  production 
while sparing synaptic NMDAR activity. This sparing is essential because 
continued synaptic NMDAR activity allows for the antioxidative mechanism 
(displayed in model) to continue functioning (Papadia et al., 2008). Future 
research should investigate ethanol’s specific antagonistic capabilities. If 
ethanol is found to be effective as currently prescribed drugs, it could not only 
be utilized in the prevention of AD and dementia, but also during the 
treatment of the pathology as well. 
PRESCRIBING ETHANOL: ISSUES 
Although ethanol could serve as a viable protective agent and possible 
intervention compound, it is not at this time seriously considered as a 
suggested method for protection or intervention. Ethanol related benefits do 
not outweigh the potential dangers, costs, and issues implicated with 
suggesting ethanol intake.  
 The first and most obvious concern is that ethanol is an intoxicant that 
possesses some harmful properties. Consumed at high levels, alcohol is 
associated with higher rates of cancer, neurological damage, and mental 
disorders (Bennett et al., 2006). Furthermore, the brain is not the most 
sensitive organ to ethanol, and harmful liver damage can occur even at 
chronic low-level intake (Anstey et al., 2009). Likewise, chronic alcohol abuse 
has been shown to facilitate progressive neurodegenerative diseases, creating 
a fine line between harmful and helpful effects in regards to ethanol intake 
(Piazza-Gardner et al., 2013). Future studies must weigh the risks and 
benefits associated with moderate ethanol consumption before seriously 
considering ethanol as a suggested protective factor. 
 Ethanol’s protective and destructive effects brings us to our second 
issue: calibrating and defining moderate ethanol consumption. The studies 
presented in this paper show great variability in their operational definition 
of “moderate ethanol consumption”. Some measure by number of drinks over 
a certain amount of time, some measure by BAC, and some attempt to 
quantify using various self-reported measures. Even within these methods 
there is great variability in what constitutes as “one drink” or “high vs. 
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moderate” intake. This exemplifies a great inconsistency between studies, 
making it difficult to compare data and results. Additionally, individual 
variability must be taken into account. The amount of ethanol in “one drink” 
may impair one individual greatly while sparing another from any 
intoxicating effects whatsoever. Body weight, alcohol tolerance, drinking 
experience, and genetic disposition are only a few of many variables that 
must be controlled in order to accurately measure beneficial effects. The 
quality of the drink and the speed in which it is consumed need also to be 
considered. Additionally, individual variability in socialness, socioeconomic 
class, race, gender, ethnicity and culture may also serve as contributing 
factors. Future studies must account for and control these variables in order 
to accurately determine the benefit of MEP.   
Conclusion 
We have thoroughly investigated the means by which ethanol consumption 
could enhance cognitive protection and have constructed a model in which 
moderate ethanol consumption could potentially stave off neurodegeneration. 
Due to the great degrees of variability and harmful physiological effects 
present throughout this review, ethanol consumption may never be a 
suggested practice to stave off AD and dementia. Although ethanol itself is 
unlikely to be utilized in practice, we have outlined its protective effects 
through various mechanisms that may assist in the discovery of more 
selective interventions in the future. The integrated model suggested within 
this paper serves as such an outline.  
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